Evidence map›Paper›PMID 40608253›Full record

ArticleDermatology and therapy2025

Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis).

Mario Valenti, Luciano Ibba, Sara Di Giulio, Paolo Dapavo, Piergiorgio Malagoli, Angelo V Marzano, Francesco Loconsole, Martina Burlando, Anna Balato, Valentina Dini and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Mario Valenti *Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. mario.valenti@hunimed.eu.ORCID http://orcid.org/0000-0001-9140-9263
Luciano Ibba *Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Sara Di GiulioDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Paolo DapavoDermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.
Piergiorgio MalagoliDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
Angelo V MarzanoDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Francesco LoconsoleDepartment of Dermatology, University of Bari, Piazza Umberto I, 1, 70121, Bari, Italy.
Martina BurlandoDepartment of Dermatology, Dipartimento di Scienze della Salute (DISSal), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Anna BalatoDermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
Valentina DiniDepartment of Dermatology, University of Pisa, Pisa, Italy.
Matteo MegnaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Giampiero GirolomoniDepartment of Medicine, Section of Dermatology, University of Verona, Verona, Italy.
Emanuele TrovatoUnit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Claudia LasagniDermatological Clinic, Department of Specialized Medicine, University of Modena, Modena, Italy.
Massimo TravagliniU.O.S.D. Dermatologica-Centro per la Cura della Psoriasi, Ospedale Perrino, Brindisi, Italy.
Claudio GuarneriDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
Nicola ZerbinatiDermatology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Simone RiberoDermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.
Francesca M GaianiDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
Carlo G CarreraDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Emanuele C CozzaniDepartment of Dermatology, Dipartimento di Scienze della Salute (DISSal), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Eugenia V Di BrizziDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
Alessandra MichelucciDepartment of Dermatology, University of Pisa, Pisa, Italy.
Luca PotestioSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Martina MaurelliDepartment of Medicine, Section of Dermatology, University of Verona, Verona, Italy.
Martina DragottoUnit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Luca MastorinoDermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.
Eleonora BongiovanniDermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.
Francesco MessinaDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
Andrea SechiDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Rossana Moroni, Rome, Italy.
Antonio CostanzoDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Alessandra NarcisiDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGuselkumab is a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA). While patients with psoriasis often achieve high clinical response rates (Psoriasis Area and Severity Index [PASI] 90 and PASI 100), the presence of PsA may influence long-term outcomes. We conducted a 260-week, multicenter, retrospective study to compare the effectiveness, safety, and drug survival of guselkumab in patients with and without concomitant PsA.

methodsA total of 1765 patients were enrolled, including 352 with a concomitant diagnosis of PsA and 1413 with isolated skin involvement. All patients were treated with guselkumab following the approved dosing schedule for moderate-to-severe plaque psoriasis for at least 1 year. Treatment effectiveness was evaluated in terms of PASI 90, PASI 100, and absolute PASI ≤ 2 at weeks 16, 28, 52, 104, 156, 204, and 260. Guselkumab drug survival was assessed using the Kaplan-Meier method at the same time points. The safety profile was evaluated by analyzing adverse events recorded in medical charts at each follow-up visit.

resultsThroughout the study period, response rates remained comparable between the two cohorts of patients, with a significant difference at 2 years of follow-up in terms of PASI 90 (80.51% versus 74.02%). Drug survival overall remained stable and similar, with 79.5% (95% confidence interval (CI) 76.9-81.9) of patients without PsA and 78.5% (95% CI 72.9-83.1) of patients with PsA still receiving guselkumab treatment after 5 years.

conclusionsOur results confirm the long-term effectiveness, persistence, and favorable safety profile of guselkumab in patients with moderate-to-severe psoriasis, regardless of the presence of concomitant PsA.

Indexed as

Anti-IL-23BiologicsGuselkumabPsoriasisPsoriatic arthritisReal-life

Identifiers

PMID40608253
PMCPMC12354356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.